Swedish drug developer Orexo is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology.
Swedish drug developer Orexo (STO: ORX) is an emerging specialty pharma company developing improved treatments using proprietary drug delivery technology. Orexo's expertise is within the area of reformulation technologies and especially sublingual formulations.
The company has a portfolio of revenue-generating US and EU approved products currently marketed under license and a pipeline of several reformulations of approved compounds for areas of unmet medical need. Orexo also has collaboration projects with several international pharmaceutical companies.
Its lead products are Zubsolv (buprenorphine and naloxone) sublingual tablet (CIII) is indicated for the maintenance treatment of opioid dependence, and Abstral which provides treatment of breakthrough pain in cancer patients. It is based on Orexo's sublingual tablet technology and the analgesic fentanyl.
It also produces Edluar, based on Orexos sublingual tablet technology and the active substance zolpidem and offers treatment for short-term insomnia. Zolpidem is a well-documented substance that has been used for a long time against insomnia. The Edluar tablet is placed under the tongue where it rapidly dissolves and the active substance is absorbed through the mucous membrane.
Other products include Diabact UBT, used to diagnose the presence of Helicobacter pylori, the bacterium that causes gastric ulcers.